Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans
about
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjectsPharmacogenetics and the concept of individualized medicine.Sucralose, a synthetic organochlorine sweetener: overview of biological issuesCytochrome P450 3A5 plays a prominent role in the oxidative metabolism of the anti-human immunodeficiency virus drug maravirocDifferential genotype dependent inhibition of CYP2C9 in humansRecent development in pharmacogenomics: from candidate genes to genome-wide association studies.Pharmacogenetics of analgesics: toward the individualization of prescription.Cytochrome P450 2C9-CYP2C9.Personalized therapy in pain management: where do we stand?Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam.Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite.Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast.Characterizing the effect of cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2D6 genetic polymorphisms on stereoselective N-demethylation of fluoxetine.The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo.Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2
P2860
Q24564755-7A1E8006-B57B-44F7-B14B-317216013746Q34562770-15830D4B-B18B-4A33-B80A-B10FE98868C0Q34657381-9C86296E-207F-4A5E-AF11-1FABB8C3AF23Q36406298-7BFAB5D5-DEC3-4461-878C-567DE2E9347FQ36732076-F83B717F-73F9-4D72-844D-CEB877BD7B07Q36874335-7CBE97E7-ECB2-4609-B13E-309ADEF8A664Q37205954-84B568E6-BA7C-4AE5-A30D-4F230A77AECBQ37691210-6FE56FD7-C5B5-4D1F-B264-D3FFC87191B2Q37760955-983BDC60-8FDB-493A-A9CE-44628F6E68A2Q37964573-AC6E66D2-5196-49CC-A226-A75DF1657072Q39232150-6A4747A5-3789-4355-BC76-F80771A7AF48Q42018917-0ECFE1FB-748C-4CE7-95DD-50A143D0CCA4Q45928715-6A959951-0069-4896-B46F-2528886F1DA9Q51058603-D4415CB6-8AA3-4546-8799-5DC577717A19Q51663926-7E819A7D-5714-4ED7-855D-7EDF9916C032Q52765416-94AF6100-28AE-413F-A998-3062D44CED4EQ55426998-1BB0D84E-8B92-4C92-95FE-C9A213595A46Q58491989-F067F183-EA73-44B8-97F1-9BA86826F653
P2860
Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Role of CYP2C9 and its variant ...... bolism of lornoxicam in humans
@ast
Role of CYP2C9 and its variant ...... bolism of lornoxicam in humans
@en
Role of CYP2C9 and its variant ...... bolism of lornoxicam in humans
@nl
type
label
Role of CYP2C9 and its variant ...... bolism of lornoxicam in humans
@ast
Role of CYP2C9 and its variant ...... bolism of lornoxicam in humans
@en
Role of CYP2C9 and its variant ...... bolism of lornoxicam in humans
@nl
prefLabel
Role of CYP2C9 and its variant ...... bolism of lornoxicam in humans
@ast
Role of CYP2C9 and its variant ...... bolism of lornoxicam in humans
@en
Role of CYP2C9 and its variant ...... bolism of lornoxicam in humans
@nl
P2093
P356
P1476
Role of CYP2C9 and its variant ...... bolism of lornoxicam in humans
@en
P2093
Dafang Zhong
J Paul Fawcett
Xiaoyan Chen
Yifan Zhang
Yingjie Guo
P304
P356
10.1124/DMD.105.003616
P407
P577
2005-06-01T00:00:00Z